| PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer A Cercek, M Lumish, J Sinopoli, J Weiss, J Shia, M Lamendola-Essel, ... New England Journal of Medicine 386 (25), 2363-2376, 2022 | 974 | 2022 |
| Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up G Argilés, J Tabernero, R Labianca, D Hochhauser, R Salazar, T Iveson, ... Annals of Oncology 31 (10), 1291-1305, 2020 | 930 | 2020 |
| Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised … C Eng, TW Kim, J Bendell, G Argilés, NC Tebbutt, M Di Bartolomeo, ... The lancet oncology 20 (6), 849-861, 2019 | 473 | 2019 |
| BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives E Sanz-Garcia, G Argiles, E Elez, J Tabernero Annals of Oncology 28 (11), 2648-2657, 2017 | 285 | 2017 |
| The spectrum of benefit from checkpoint blockade in hypermutated tumors B Rousseau, MB Foote, SB Maron, BH Diplas, S Lu, G Argilés, A Cercek, ... New England Journal of Medicine 384 (12), 1168-1170, 2021 | 183 | 2021 |
| Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary … J Tabernero, I Melero, W Ros, G Argiles, A Marabelle, ME Rodriguez-Ruiz, ... Journal of Clinical Oncology 35 (15_suppl), 3002-3002, 2017 | 172 | 2017 |
| Tankyrase inhibition blocks Wnt/β-catenin pathway and reverts resistance to PI3K and AKT inhibitors in the treatment of colorectal cancer O Arqués, I Chicote, I Puig, SP Tenbaum, G Argilés, R Dienstmann, ... Clinical cancer research 22 (3), 644-656, 2016 | 172 | 2016 |
| Efficacy of Sym004 in patients with metastatic colorectal cancer with acquired resistance to anti-EGFR therapy and molecularly selected by circulating tumor DNA analyses: a … C Montagut, G Argilés, F Ciardiello, TT Poulsen, R Dienstmann, M Kragh, ... JAMA oncology 4 (4), e175245-e175245, 2018 | 118 | 2018 |
| TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence I Puig, SP Tenbaum, I Chicote, O Arques, J Martinez-Quintanilla, ... The Journal of clinical investigation 128 (9), 3887-3905, 2018 | 103 | 2018 |
| A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells I Puig, I Chicote, SP Tenbaum, O Arqués, JR Herance, JD Gispert, ... Clinical Cancer Research 19 (24), 6787-6801, 2013 | 98 | 2013 |
| First-line treatment of metastatic colorectal cancer: interpreting FIRE-3, PEAK, and CALGB/SWOG 80405 E Elez, G Argilés, J Tabernero Current treatment options in oncology 16, 1-12, 2015 | 96 | 2015 |
| Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours J Rodon, G Argilés, RM Connolly, U Vaishampayan, M de Jonge, ... British journal of cancer 125 (1), 28-37, 2021 | 92 | 2021 |
| Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer R Dienstmann, A Patnaik, R Garcia-Carbonero, A Cervantes, M Benavent, ... Cancer Discovery 5 (6), 598-609, 2015 | 83 | 2015 |
| Transcriptional subtyping and CD8 immunohistochemistry identifies patients with stage II and III colorectal cancer with poor prognosis who benefit from adjuvant chemotherapy WL Allen, PD Dunne, S McDade, E Scanlon, M Loughrey, HG Coleman, ... JCO precision oncology 2, 1-15, 2018 | 72 | 2018 |
| The first-in-class anti-EGFR antibody mixture Sym004 overcomes cetuximab resistance mediated by EGFR extracellular domain mutations in colorectal cancer FJ Sánchez-Martín, B Bellosillo, M Gelabert-Baldrich, A Dalmases, ... Clinical Cancer Research 22 (13), 3260-3267, 2016 | 72 | 2016 |
| Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours SA Piha-Paul, PN Munster, A Hollebecque, G Argilés, O Dajani, ... European Journal of Cancer 51 (14), 1865-1873, 2015 | 67 | 2015 |
| Safety, pharmacokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719: Results from the first-in-human study. AM Gonzalez-Angulo, D Juric, G Argilés, JHM Schellens, HA Burris, ... Journal of Clinical Oncology 31 (15_suppl), 2531-2531, 2013 | 65 | 2013 |
| Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer T Yoshino, G Argilés, E Oki, E Martinelli, H Taniguchi, D Arnold, ... Annals of Oncology 32 (12), 1496-1510, 2021 | 64 | 2021 |
| Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study E Van Cutsem, T Yoshino, HJ Lenz, S Lonardi, A Falcone, ML Limón, ... Annals of Oncology 29 (9), 1955-1963, 2018 | 63 | 2018 |
| Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial G Argilés, MP Saunders, F Rivera, A Sobrero, CG Ponce, S Cascinu, ... European journal of cancer 51 (8), 942-949, 2015 | 62 | 2015 |
Jordi RodonMD Anderson Cancer Center在 mdanderson.org 的电子邮件经过验证
